Cancer-related fatigue remains one of the most difficult and frustrating symptoms experienced by people living with cancer. Unlike normal tiredness, this form of exhaustion often affects physical strength, emotional well-being, focus, and everyday functioning. Even after rest, many patients continue to feel drained. A newly updated meta-analysis published in the Journal of the National Comprehensive Cancer Network suggests that methylphenidate-type psychostimulants may offer meaningful relief for some patients struggling with cancer-related fatigue.
The study, led by Bruno Almeida Costa and colleagues, reviewed randomized controlled trials evaluating methylphenidate and dexmethylphenidate in cancer patients experiencing fatigue. Published in May 2026, the research provides one of the most comprehensive evaluations to date on whether stimulant medications can safely and effectively improve fatigue symptoms in oncology care.
According to the National Comprehensive Cancer Network, cancer-related fatigue is a persistent feeling of physical, emotional, or cognitive exhaustion linked to cancer or its treatment. It differs from ordinary tiredness because it is often disproportionate to activity levels and significantly interferes with daily life.
Research shows that nearly half to more than two-thirds of cancer patients experience fatigue during treatment or advanced illness. Causes are complex and may include inflammation, hormone imbalance, sleep disruption, muscle dysfunction, emotional stress, chemotherapy side effects, and changes in brain signaling pathways.
Doctors typically recommend non-drug strategies first, including exercise, counseling, mindfulness practices, yoga, and psychosocial support. However, these interventions may take weeks or months to provide noticeable improvement. That delay has led researchers to investigate whether psychostimulant medications can provide faster symptom relief.
Methylphenidate, commonly known by brand names such as Ritalin and Concerta, is widely prescribed for attention-deficit/hyperactivity disorder and narcolepsy. Dexmethylphenidate is a related medication that contains the more active component of methylphenidate.
These medications work by increasing dopamine and norepinephrine activity in the brain. Researchers believe these neurotransmitters may help improve alertness, concentration, motivation, and energy levels in patients affected by cancer-related fatigue.
Although these stimulants have been discussed in oncology guidelines for years, evidence from earlier studies produced mixed results. The latest analysis aimed to clarify whether the medications truly provide measurable benefits.
The researchers performed a systematic review and meta-analysis using data from nine randomized, placebo-controlled clinical trials published between 2006 and 2024. In total, 823 patients participated in the included studies.
Trials evaluated either methylphenidate or dexmethylphenidate in adults with advanced cancer or individuals actively receiving cancer treatment. Researchers analyzed fatigue outcomes using several validated measurement tools, including the Functional Assessment of Chronic Illness Therapy-Fatigue scale, commonly known as FACIT-F.
The review followed internationally recognized research standards, including PRISMA reporting guidelines and Cochrane review methodology. Databases searched included PubMed, Embase, and the Cochrane Central Register of Controlled Trials.
The updated analysis found that psychostimulant treatment produced statistically significant improvements in fatigue across multiple assessment scales.
Using the FACIT-F scoring system, researchers observed an average improvement of 2.43 points compared with placebo. While that number fell slightly below the threshold generally considered strongly clinically meaningful, additional subgroup analyses revealed more encouraging results over time.
At approximately five weeks of treatment, improvements became clinically meaningful, with fatigue scores improving by an average of 3.56 points. Benefits appeared even greater after eight weeks, reaching nearly four points on the FACIT-F scale.
The researchers concluded that the medications delivered a modest but consistent reduction in cancer-related fatigue symptoms.
Importantly, shorter studies often showed smaller benefits. Many early trials evaluated outcomes within only two weeks, which may not have allowed enough time for dose adjustment and sustained therapeutic effects.
One of the most reassuring findings from the study involved medication safety. Researchers found no statistically significant increase in common adverse effects compared with placebo.
Side effects analyzed included:
The authors noted that careful patient selection remains important. Most clinical trials excluded patients with serious cardiovascular disease or major psychiatric disorders, meaning results may not apply equally to every patient population.
The study also emphasized the importance of gradual dose titration and regular monitoring during treatment.
Cancer-related fatigue is often underestimated despite its major impact on quality of life. Patients may struggle to work, exercise, socialize, or maintain independence. Some experience profound mental fatigue that affects memory and concentration.
The updated findings may help bridge a long-standing gap in supportive cancer care. While current guidelines from organizations such as the American Society of Clinical Oncology remain cautious about routine psychostimulant use, the new evidence suggests these medications may benefit carefully selected patients, especially when other approaches are unavailable or slow to work.
Researchers proposed that psychostimulants could potentially serve as a temporary supportive strategy while longer-term interventions such as physical activity programs or psychotherapy begin taking effect.
According to the study authors, patients who may be good candidates for methylphenidate-type medications include those with:
However, caution is advised in individuals with uncontrolled anxiety, insomnia, heart disease, or psychiatric instability.
The authors emphasized that stimulant medications should complement, not replace, first-line nonpharmacologic treatments such as exercise, cognitive behavioral therapy, mindfulness, yoga, tai chi, and psychosocial support.
Although results were promising, the researchers acknowledged several limitations.
The included studies varied considerably in:
Some studies were also relatively small and included older populations with advanced illness. In addition, placebo responses were substantial in several trials, which may have reduced the apparent treatment effect.
The authors called for larger and longer clinical trials with more standardized patient populations and follow-up periods.
This updated meta-analysis strengthens the evidence supporting methylphenidate-type psychostimulants as a potential treatment option for cancer-related fatigue. While benefits appear modest overall, clinically meaningful improvements became more apparent after several weeks of therapy.
For carefully selected patients, especially those with advanced cancer or severe fatigue symptoms, these medications may offer an additional tool to improve daily functioning and quality of life.
As cancer survivorship continues to grow, supportive care strategies aimed at reducing fatigue will likely become an increasingly important part of comprehensive oncology treatment.
Costa BA, Sheppard R, Coelho HGB, et al. Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network. Volume 24, Issue 5, May 2026. DOI: 10.6004/jnccn.2025.7135.
This article is for educational and informational purposes only and does not constitute medical advice. Patients should consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan. The safety and effectiveness of methylphenidate for cancer-related fatigue may vary depending on individual medical history, cancer type, and overall health condition.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.